Irena Loryan
Forskare vid Institutionen för farmaci; Translationell PKPD
- Telefon:
- 018-471 49 95
- E-post:
- irena.loryan@farmbio.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Irena Loryan vid Institutionen för farmaci; Translationell PKPD
Forskare vid Institutionen för farmaci; Translationell PKPD
- E-post:
- irena.loryan@farmaci.uu.se
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Irena Loryan vid Institutionen för farmaci; Translationell PKPD
Forskare vid Institutionen för farmaci; Translationell PKPD
- Besöksadress:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postadress:
- Box 580
751 23 UPPSALA
Ladda ned kontaktuppgifter för Irena Loryan vid Institutionen för farmaci; Translationell PKPD
- ORCID:
- 0000-0002-1557-4416
Mer information visas för dig som medarbetare om du loggar in.
Nyckelord
- blood-brain barrier
- blood-csf barrier
- blood-dorsal root ganglia barrier
- blood-nerve barrier
- brain drug delivery
- cns barriers
- neurodegeneration
- neuropharmacokinetics
Biografi
Associate Professor (Docent) Irena Loryan is a researcher in the translational Pharmacokinetics-Pharmacodynamics (tPKPD) group in the Department of Pharmacy, Uppsala University, Sweden. She received her M.D. in 2001 and Ph.D. in pharmacology and biochemistry in 2007 from Yerevan State Medical University, Armenia. She then worked as a post-doctoral fellow at the Division of Pharmacogenetics at the Department of Pharmacology and Physiology, Karolinska Institutet (Prof. Magnus Ingelman-Sundberg Lab). Since 2011, she worked as a post-doctoral fellow at the Department of Pharmaceutical Biosciences, Uppsala University (Prof. Margareta Hammarlund-Udenaes Lab) in collaboration with Janssen Pharmaceutica, Beerse, Belgium. Her current research interest focuses on neuropharmacokinetics, implying mechanistic understanding of drug disposition in central and peripheral nervous systems involving passage across CNS and PNS barriers, distribution within parenchyma and elimination processes in health and disease, with focus on neurodegenerative diseases.
Publikationer
Urval av publikationer
- Unbound Brain-to-Plasma Partition Coefficient, K-p,K-uu,K-brain-a Game Changing Parameter for CNS Drug Discovery and Development (2022)
- Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. (2021)
- Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls (2019)
- In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions (2016)
- Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates (2015)
- Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery (2014)
- The brain slice method for studying drug distribution in the CNS (2013)
Senaste publikationer
- Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy (2024)
- The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier (2024)
- Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity (2023)
- Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences (2023)
- Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro (2023)
Alla publikationer
Artiklar
- Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy (2024)
- The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier (2024)
- Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity (2023)
- Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences (2023)
- Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro (2023)
- Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution (2023)
- Brain barriers virtual (2022)
- Unbound Brain-to-Plasma Partition Coefficient, K-p,K-uu,K-brain-a Game Changing Parameter for CNS Drug Discovery and Development (2022)
- Professor Margareta Hammarlund-Udenaes - Humbled Scientist Shaping Modern Neuropharmacokinetics (2022)
- Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. (2021)
- Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis (2020)
- Heterogeneous drug tissue binding in brain regions of rats, Alzheimer’s patients and controls (2019)
- Amorphisation of Free Acid Ibuprofen and Other Profens in Mixtures with Nanocellulose (2019)
- Mechanistic Study on the Use of the L-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug (2019)
- Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution (2019)
- Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis (2017)
- In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions (2016)
- Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates (2015)
- Effect of transporter inhibition on the distribution of cefadroxil in rat brain (2014)
- Mechanistic Understanding of Brain Drug Disposition to Optimize the Selection of Potential Neurotherapeutics in Drug Discovery (2014)
- Sex difference in formation of propofol metabolites (2013)
- The brain slice method for studying drug distribution in the CNS (2013)
- UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems (2012)
- Influence of sex on propofol metabolism, a pilot study (2012)
- Dual behavior of cyclic peptides at the blood-brain barrier vs brain cellular uptake: Importance for CNS drug development
- Cellular uptake and intra-brain distribution of cyclic cell penetrating peptides: why tissue and cell type matters